MarketCap
Facebook
X
TelegramQuarterly report 2025-Q1
added 04-22-2025
Danaher Corporation Accounts Receivables 2011-2025 | DHR
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables Danaher Corporation
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.54 B | 3.92 B | 4.1 B | 4.63 B | 4.04 B | 3.19 B | 3.49 B | 3.52 B | 3.19 B | 2.99 B | 3.45 B | 3.45 B | 3.27 B | 3.05 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 4.63 B | 2.99 B | 3.56 B |
Quarterly Accounts Receivables Danaher Corporation
| 2025-Q1 | 2024-Q4 | 2024-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.51 B | 3.54 B | - | - | - | 4.53 B | 4.41 B | 4.63 B | 4.19 B | 4.1 B | 4.63 B | 4.04 B | 4.04 B | 4.04 B | 4.04 B | 3.19 B | 3.19 B | 3.19 B | 3.19 B | 3.03 B | 3.49 B | 3.49 B | 3.49 B | 3.52 B | 3.52 B | 3.52 B | 3.52 B | 3.19 B | 3.19 B | 3.19 B | 3.19 B | 2.99 B | 2.99 B | 3.96 B | 3.96 B | 3.45 B | 3.45 B | 3.63 B | 3.63 B | 3.29 B | 3.45 B | 3.45 B | 3.45 B | 3.27 B | 3.27 B | 3.27 B | 3.27 B | 3.05 B | 3.05 B | 3.05 B | 3.05 B |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 4.63 B | 2.99 B | 3.54 B |
Accounts Receivables of other stocks in the Diagnostics research industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Akumin
AKU
|
114 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Accelerate Diagnostics
AXDX
|
2.42 M | - | -61.36 % | $ 2.46 M |  USA |
 |
Burning Rock Biotech Limited
BNR
|
88.2 M | $ 21.0 | 1.82 % | $ 226 M |  China |
 |
Co-Diagnostics
CODX
|
304 K | $ 0.18 | -1.55 % | $ 5.28 M | USA |
 |
Biocept
BIOC
|
2.15 M | - | -13.05 % | $ 7.29 M | USA |
 |
Chembio Diagnostics
CEMI
|
6.54 M | - | 0.22 % | $ 16.8 M | USA |
 |
Castle Biosciences
CSTL
|
51.2 M | $ 39.22 | -0.24 % | $ 1.09 B | USA |
 |
DarioHealth Corp.
DRIO
|
3.16 M | $ 10.5 | -1.87 % | $ 298 M |  Israel |
 |
BioNano Genomics
BNGO
|
4.75 M | $ 1.51 | 0.67 % | $ 1.92 M | USA |
 |
Exact Sciences Corporation
EXAS
|
249 M | $ 101.9 | - | $ 18.9 B | USA |
 |
DexCom
DXCM
|
974 M | $ 66.82 | -0.37 % | $ 25.8 B | USA |
 |
Enzo Biochem
ENZ
|
3.99 M | - | -8.98 % | $ 14.8 K | USA |
 |
Fulgent Genetics
FLGT
|
69 M | $ 26.28 | -0.79 % | $ 795 M | USA |
 |
Global Cord Blood Corporation
CO
|
416 M | - | - | $ 399 M | China |
 |
DermTech
DMTK
|
2.58 M | - | -11.32 % | $ 2.94 M | USA |
 |
CareDx, Inc
CDNA
|
51.1 M | $ 18.79 | -1.49 % | $ 1.01 B | USA |
 |
Heska Corporation
HSKA
|
29.5 M | - | - | $ 1.31 B | USA |
 |
Anixa Biosciences
ANIX
|
173 K | $ 3.11 | -0.32 % | $ 99.2 K | USA |
 |
HTG Molecular Diagnostics
HTGM
|
1.42 M | - | -20.0 % | $ 1.06 M | USA |
 |
IQVIA Holdings
IQV
|
3.2 B | $ 226.18 | -0.65 % | $ 41 B | USA |
 |
Guardant Health
GH
|
110 M | $ 102.07 | 1.46 % | $ 12.5 B | USA |
 |
Aspira Women's Health
AWH
|
1.24 M | - | -6.19 % | $ 10.5 M | USA |
 |
Myriad Genetics
MYGN
|
121 M | $ 6.17 | - | $ 559 M | USA |
 |
ENDRA Life Sciences
NDRA
|
6.85 K | $ 4.55 | -4.41 % | $ 2.44 M | USA |
 |
Neogen Corporation
NEOG
|
153 M | $ 7.05 | -0.07 % | $ 1.53 B | USA |
 |
Personalis
PSNL
|
8.14 M | $ 7.93 | -0.5 % | $ 470 M | USA |
 |
National Research Corporation
NRC
|
12.4 M | $ 18.42 | -1.26 % | $ 452 M | USA |
 |
RadNet
RDNT
|
186 M | $ 71.33 | -0.22 % | $ 5.21 B | USA |
 |
Illumina
ILMN
|
735 M | $ 131.5 | -0.94 % | $ 20.9 B | USA |
 |
Charles River Laboratories International
CRL
|
721 M | $ 201.1 | -0.44 % | $ 10.3 B | USA |
 |
Soleno Therapeutics
SLNO
|
133 K | $ 45.22 | -2.32 % | $ 1.82 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
1.3 B | $ 174.8 | -0.4 % | $ 19.4 B | USA |
|
Biodesix
BDSX
|
8.6 M | $ 6.61 | -1.64 % | $ 857 M | USA |
 |
Motus GI Holdings
MOTS
|
76 K | - | -34.28 % | $ 263 K | Israel |
 |
Laboratory Corporation of America Holdings
LH
|
1.94 B | $ 252.06 | -0.4 % | $ 21.1 B | USA |
 |
ICON Public Limited Company
ICLR
|
1.34 B | $ 182.26 | -0.4 % | $ 15 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
474 M | $ 681.09 | -0.18 % | $ 56.2 B | USA |
 |
Lantheus Holdings
LNTH
|
321 M | $ 66.97 | -0.28 % | $ 4.63 B | USA |
 |
Mettler-Toledo International
MTD
|
687 M | $ 1 404.2 | -0.72 % | $ 29.8 B |  Schweiz |